Literature DB >> 30087054

[New developments in the management of nasopharyngeal carcinoma].

P Blanchard1, F Nguyen2, A Moya-Plana3, J P Pignon4, C Even3, F Bidault5, S Temam3, A Ruffier2, Y Tao2.   

Abstract

Nasopharyngeal carcinoma is a rare condition, with less than 300 cases occurring per year in France. Its treatment can be difficult due to the importance of side effects, but tumor control is usually excellent following a well conducted chemoradiotherapy. This article summarizes the recent advances in nasopharyngeal cancer diagnosis, classification, treatment, surveillance and management of recurrences. Chemotherapy timing is discussed, along with arguments in favor of induction chemotherapy in locally advanced cases. As a survival advantage has been suggested for when patients are treated in high volume center it seems reasonable to refer these young patients for treatment to tertiary expert centers, especially given the low incidence of the disease.
Copyright © 2018 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer du nasopharynx; Chemotherapy; Chimiothérapie; Epstein Barr virus; Meta-analysis; Méta-analyse; Nasopharyngeal cancer; Radiotherapy; Radiothérapie; Virus Epstein Barr

Mesh:

Year:  2018        PMID: 30087054     DOI: 10.1016/j.canrad.2018.06.003

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism.

Authors:  Xixia Zhang; Jing Yang; Dong Shi; Zhiwei Cao
Journal:  Cancer Cell Int       Date:  2020-08-03       Impact factor: 5.722

2.  MiR-154-5p Suppresses Cell Invasion and Migration Through Inhibiting KIF14 in Nasopharyngeal Carcinoma.

Authors:  Jie Chen; Chengxian Ma; Yufeng Zhang; Shuai Pei; Mingyu Du; Yujie Zhang; Luxi Qian; Jianlin Wang; Li Yin; Xia He
Journal:  Onco Targets Ther       Date:  2020-03-13       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.